Hospital da Luz Lisboa

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Crohn's disease2 trials
• Obesity2 trials
• Aortic stenosis1 trial
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Fabry disease1 trial
• Gastric and oesophageal cancer1 trial
• Lung cancer1 trial
• Metastatic breast cancer1 trial
• Prostate cancer1 trial
• Ulcerative colitis1 trial

Phase

• Phase 33 trials
• Phase 1/21 trial
• Phase 21 trial

Status

• Recruiting5 trials
• Not yet recruiting3 trials
• Completed1 trial
• Withdrawn1 trial

Lead sponsor

• Eli Lilly and Company4 trials
• GLSMED Learning Health S.A.2 trials
• Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1 trial
• Eikon Therapeutics1 trial
• Portuguese Association of Interventional Cardiology1 trial
• and 1 more

Running trials

• Recruiting

  Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

  NCT07817875· Phase 3· Eli Lilly and Company· Source

  Contact: Julia Galhardo (principal investigator)

• Recruiting

  Prospective Risk Evaluation and Detection of Crohn's Disease in First-degree Relatives

  NCT07316621· GLSMED Learning Health S.A.· Source

  Contact: Ana F Raimundo, Ph.D

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Eli Lilly and Company· Source

  Contact: Lidia Ramos (principal investigator)

• Recruiting

  EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

  NCT07262619· Phase 1/2· Eikon Therapeutics· Source

  Contact: Ana C Mamede, PharmD

• Recruiting

  PERFECT - Portuguese Evolut Registry Studying the Outcomes of Medtronic Evolut™ FX+ TAVI System by Evaluating an Optimal Care Pathway for TAVI

  NCT07343674· Portuguese Association of Interventional Cardiology· Source

  Contact: Pedro Gonçaves, MD, PhD

• Recruiting

  Glycan Supplementation on a Human Model of Crohn's Disease Initiation and Progression

  NCT06727253· GLSMED Learning Health S.A.· Source

  Contact: Catarina Barbosa

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

  Contact: Joao Moreira Pinto (principal investigator)

• Recruiting

  A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  NCT06672549· Phase 3· Eli Lilly and Company· Source

  Contact: Julia Galhardo (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease2 recruiting
• Obesity2 recruiting
• Aortic stenosis1 recruiting
• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Lung cancer1 recruiting
• Prostate cancer1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Recruiting

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source

• Completed

  Screening of Fabry Disease in Portuguese Patients With Idiopathic Cardiomyopathies

  NCT05409846· Universidade do Porto· Source